Katie L. Mycock, MChem

Associate Manager, Observational Research
Adelphi Real World, United Kingdom

Disclosure(s): ViiV Healthcare: Adelphi Real World were paid consultants (CRO) to conduct the observational research study on behalf of ViiV Healthcare, Adelphi Real World were paid consultants (CRO) to conduct the observational research study on behalf of ViiV Healthcare

Poster(s):

• 1278 - Real World Treatment Experience of Single Tablet Dolutegravir/Lamivudine in Those Naïve to Treatment with Baseline Viral Loads ≥ 100,000 copies/mL in the US
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1279 - Real World Treatment Experience of Treatment-Naïve People with HIV who Initiated Treatment with Single Tablet Dolutegravir/Lamivudine in a Test and Treat setting in the US.
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET